UNLABELLED: The analysis of inflammatory cytokines and chemokines produced during hepatitis C virus (HCV) infection has advanced our understanding of viral-host interactions and identified predictors of treatment response. Administration of interferons (IFNs) made it difficult to interpret biomarkers of immune activation during treatment. Direct-acting antiviral (DAA) regimens without IFN are now being used to treat HCV with excellent efficacy. To gain insight into HCV-host interactions occurring before, during, and after HCV treatment, we performed a case-control study that measured serial plasma levels of IFN-γ-inducible protein 10 (IP-10), monocyte chemoattractant protein 1 (MCP-1), macrophage inflammatory protein 1 beta (MIP-1β), and interleukin-18 (IL-18) in 131 patients with chronic HCV treated with sofosbuvir (SOF) plus ribavirin (RBV). A linear regression analysis using baseline factors identified strong positive associations between elevated alanine aminotransferase and pretreatment IP-10 and between the presence of cirrhosis and elevated pretreatment IL-18. Mean IP-10, MCP-1, MIP-1β, and IL-18 levels all decline on therapy, but display different dynamics late in treatment and after cessation of therapy. On treatment, IP-10 and MIP-1β levels were significantly higher in individuals who achieved sustained virological response (SVR). Logistic regression analyses examining treatment response in all patients demonstrated significant associations between higher baseline MIP-1β levels and smaller decreases in MIP-1β early in treatment and SVR. Higher early MIP-1β levels were also significantly associated with SVR in subsets of patients with cirrhosis and individuals with genotype 3 (GT3) infection, two factors associated with decreased responsiveness to treatment. CONCLUSION: Changes in IP-10 levels mirror HCV RNA, suggesting that IP-10 is an indicator of innate immune viral recognition. MIP-1β levels remain elevated in GT2/3 patients who achieved SVR, suggesting differential immune activation in those who respond to SOF/RBV therapy and a potential role in predicting treatment responses.
UNLABELLED: The analysis of inflammatory cytokines and chemokines produced during hepatitis C virus (HCV) infection has advanced our understanding of viral-host interactions and identified predictors of treatment response. Administration of interferons (IFNs) made it difficult to interpret biomarkers of immune activation during treatment. Direct-acting antiviral (DAA) regimens without IFN are now being used to treat HCV with excellent efficacy. To gain insight into HCV-host interactions occurring before, during, and after HCV treatment, we performed a case-control study that measured serial plasma levels of IFN-γ-inducible protein 10 (IP-10), monocyte chemoattractant protein 1 (MCP-1), macrophage inflammatory protein 1 beta (MIP-1β), and interleukin-18 (IL-18) in 131 patients with chronic HCV treated with sofosbuvir (SOF) plus ribavirin (RBV). A linear regression analysis using baseline factors identified strong positive associations between elevated alanine aminotransferase and pretreatment IP-10 and between the presence of cirrhosis and elevated pretreatment IL-18. Mean IP-10, MCP-1, MIP-1β, and IL-18 levels all decline on therapy, but display different dynamics late in treatment and after cessation of therapy. On treatment, IP-10 and MIP-1β levels were significantly higher in individuals who achieved sustained virological response (SVR). Logistic regression analyses examining treatment response in all patients demonstrated significant associations between higher baseline MIP-1β levels and smaller decreases in MIP-1β early in treatment and SVR. Higher early MIP-1β levels were also significantly associated with SVR in subsets of patients with cirrhosis and individuals with genotype 3 (GT3) infection, two factors associated with decreased responsiveness to treatment. CONCLUSION: Changes in IP-10 levels mirror HCV RNA, suggesting that IP-10 is an indicator of innate immune viral recognition. MIP-1β levels remain elevated in GT2/3 patients who achieved SVR, suggesting differential immune activation in those who respond to SOF/RBV therapy and a potential role in predicting treatment responses.
Authors: Jama M Darling; Jeroen Aerssens; Gregory Fanning; John G McHutchison; David B Goldstein; Alexander J Thompson; Kevin V Shianna; Nezam H Afdhal; Michael L Hudson; Charles D Howell; Willem Talloen; Jacques Bollekens; Mieke De Wit; Annick Scholliers; Michael W Fried Journal: Hepatology Date: 2011-01 Impact factor: 17.425
Authors: Daniel P Barr; Gabrielle T Belz; Patrick C Reading; Magdalena Wojtasiak; Paul G Whitney; William R Heath; Francis R Carbone; Andrew G Brooks Journal: Eur J Immunol Date: 2007-05 Impact factor: 5.532
Authors: Patrick C Reading; Paul G Whitney; Daniel P Barr; Magdalena Wojtasiak; Justine D Mintern; Jason Waithman; Andrew G Brooks Journal: J Immunol Date: 2007-09-01 Impact factor: 5.422
Authors: Martin Lagging; Galia Askarieh; Francesco Negro; Stephanie Bibert; Jonas Söderholm; Johan Westin; Magnus Lindh; Ana Romero; Gabriele Missale; Carlo Ferrari; Avidan U Neumann; Jean-Michel Pawlotsky; Bart L Haagmans; Stefan Zeuzem; Pierre-Yves Bochud; Kristoffer Hellstrand Journal: PLoS One Date: 2011-02-24 Impact factor: 3.240
Authors: Donald D Anthony; Mark S Sulkowski; Laura M Smeaton; Sofi Damjanovska; Carey L Shive; Corinne M Kowal; Daniel E Cohen; Debika Bhattacharya; Beverly L Alston-Smith; Ashwin Balagopal; David L Wyles Journal: J Infect Dis Date: 2020-09-14 Impact factor: 5.226
Authors: Ashwin Balagopal; Laura M Smeaton; Jeffrey Quinn; Charles S Venuto; Gene D Morse; Vincent Vu; Beverly Alston-Smith; Daniel E Cohen; Jorge L Santana-Bagur; Donald D Anthony; Mark S Sulkowski; David L Wyles; Andrew H Talal Journal: J Infect Dis Date: 2020-07-23 Impact factor: 7.759
Authors: Robert G Wallace; Laura C Twomey; Marc-Antoine Custaud; Niall Moyna; Philip M Cummins; Marco Mangone; Ronan P Murphy Journal: Biomed Res Int Date: 2016-01-28 Impact factor: 3.411